Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.
about
Early and long-term outcome of elective stenting of the infarct-related artery in patients with viability in the infarct-area: Rationale and design of the Viability-guided Angioplasty after acute Myocardial Infarction-trial (The VIAMI-trial)Coagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparinEvaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitorsPharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplastyPEGylation of Truncated Streptokinase Leads to Formulation of a Useful Drug with Ameliorated Attributesα2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke.Anticoagulation in the management of non-ST-segment elevation acute coronary syndrome.The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the Atrial Fibrillation undergoing Coronary Artery Stenting study.Impact of chronic oral anticoagulation on management and outcomes of patients with acute myocardial infarction: data from the RICO survey.Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment.Pharmacology and clinical use of bivalirudin.Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention.Drug insight: bleeding after percutaneous coronary intervention-risks, measures and impact of anticoagulant treatment options.Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention.Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention.Feasibility and safety of percutaneous coronary intervention in patients with end-stage liver disease referred for liver transplantation.Tolerability and feasibility of eptifibatide in acute coronary syndrome in patients at high risk for cardiovascular disease: A retrospective analysis.Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta-analysis.ABCIXIMAB: a new antiaggregant used in angioplasty.The Thrombolysis in Myocardial Infarction (TIMI) trials: the first decade.Percutaneous transluminal coronary angioplasty: catheter technology and procedural guidelinesMeasurement of cardiac reserve in cardiogenic shock: implications for prognosis and management.Ischaemic left ventricular failure: evidence of sustained benefit after 18 months' treatment with xamoterol.Impact of renal dysfunction on long-term outcomes of elderly patients with acute coronary syndrome: a longitudinal, prospective observational study.Clinical review: bleeding - a notable complication of treatment in patients with acute coronary syndromes: incidence, predictors, classification, impact on prognosis, and managementIndividualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbitsDifferentiating pharmacologic agents used in catheter-directed thrombolysis.A decade of changes in clinical characteristics and management of elderly patients with non-ST elevation myocardial infarction admitted in Italian cardiac care units.Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics.Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention.Tailored antiplatelet therapy and clinical adverse outcomes.Glycoprotein IIb/IIIa receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome.Point of care platelet activity measurement in primary PCI [PINPOINT-PPCI]: a protocol paper.Influence of Access, Anticoagulant, and Bleeding Definition on Outcomes of Primary Percutaneous Coronary Intervention: Early Experience of an US Academic CenterAnti-platelet therapy: ADP receptor antagonists.Effectiveness and cost effectiveness of single bolus treatment with abciximab (Reo Pro) in preventing restenosis following percutaneous transluminal coronary angioplasty in high risk patientsOutcomes with changes in prescribing of glycoprotein IIb/IIIa inhibitors in PCI.Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data.
P2860
Q24800495-383EFF55-1559-43FD-9BF6-5F1904ECDD3EQ28208874-17E0F82E-DCAD-46ED-A88A-946040DF0A84Q28213564-0E23FF2E-3226-4910-9448-825C3D7C636AQ28360267-67526DEF-9745-48C7-8CA7-3158863274D0Q28552198-52E8B07B-73A7-473C-9B20-3C9C1F50D2DCQ30248728-B571E590-25D3-4C54-A9EA-CBAD7296FE76Q30402038-077FBA24-F9EB-41AD-8AE0-FCD96E86B195Q30647865-0A4BD241-26C0-4925-9A60-2F59A5CDC844Q33230636-38EC0D25-86EC-4895-8D1E-1AC3699022F5Q33331255-CCB6AC05-CA27-431B-9F56-5C732F44AEF3Q33342507-3EB18D25-B417-416C-8455-E03C05ED70D5Q33367950-A3ACF65D-0608-4BEB-BA24-60B5A19D0731Q33369119-62C93925-4A64-4D88-977E-CB505FF996AEQ33370967-8B87D3D7-2C93-44D6-A54A-A805F37EB11AQ33376977-894C88D1-8E1F-4FD5-A189-010E66A0DEE6Q33394599-43964935-BB04-46A4-99E5-D87A1B326BB4Q33414284-A48E306A-D030-414B-96E4-736BCF23B7BEQ33441432-7BA0BF42-5F65-446A-8C71-B66119F52AFDQ33497071-63E65EA9-9749-4232-A87A-8587E207F05EQ33568780-C71E8EC8-FDE4-431F-B13E-63341D38C244Q33610230-E384BFDC-2F92-45AD-A9EA-C55842E6DA90Q33610420-AD223652-A1E3-4BBC-9C87-410953FF52EFQ33610465-7A339461-D9D0-426F-9E51-2276668CF322Q33716941-AF39B27F-FA40-4BB4-917D-D76D75621751Q33750028-8D0A8DFD-A602-430C-A384-2DEF0107063FQ33804996-019BFAD5-D125-4D41-99F9-25F99BC072D9Q33848439-D5F14EB9-8475-4FBE-9FB3-AE8B519146F6Q34563249-F9FF2525-1AFA-422F-92F8-1550E5627559Q34707768-CBD76C50-B942-4E5B-8916-25CEEC0A123BQ34716730-B2E5F036-77C7-4FC5-93BC-4D4AA3FAD586Q34805121-187A9630-0B02-4727-BB7D-098ED297F803Q34906975-A0C24598-2DF6-473F-A404-401721AAA86AQ35032042-188A542B-BBEB-4A6B-B0A3-62EE538B5F30Q35139249-357B8E42-619D-48A1-9BED-250314968BD8Q35141218-97F925F0-8630-4BB6-B4FD-32E7BCF8CCB6Q35141545-06A4DF82-2A26-4906-9961-D6856F841295Q35278165-FF48484A-1E99-4096-BA15-EBCD8678453DQ35366286-07016A0E-A652-4046-8E10-9094F913D1AFQ35547240-AD1BE8DE-4DA5-4102-95BF-BF096644656BQ35569714-242A3FC8-8C3F-4693-9831-C90B8B41C81C
P2860
Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.
description
1988 nî lūn-bûn
@nan
1988 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Thrombolysis in Myocardial Inf ...... n activator and streptokinase.
@ast
Thrombolysis in Myocardial Inf ...... n activator and streptokinase.
@en
type
label
Thrombolysis in Myocardial Inf ...... n activator and streptokinase.
@ast
Thrombolysis in Myocardial Inf ...... n activator and streptokinase.
@en
prefLabel
Thrombolysis in Myocardial Inf ...... n activator and streptokinase.
@ast
Thrombolysis in Myocardial Inf ...... n activator and streptokinase.
@en
P2093
P921
P1476
Thrombolysis in Myocardial Inf ...... n activator and streptokinase.
@en
P2093
Knatterud G
Robertson TL
Schreiber TL
P356
10.1016/0735-1097(88)90158-1
P407
P577
1988-01-01T00:00:00Z